Children's Hospital and Regional Medical Center, University of Washington, Seattle, Washington 98105
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Plasminogen activator inhibitor-1 (PAI-1) is a serine protease inhibitor that was isolated 20 years ago. First recognized as an inhibitor of intravascular fibrinolysis, it is now evident that PAI-1 is a multifunctional protein with actions that may be dependent on or independent of its protease inhibitory effects. The latter often involve interactions between PAI-1 and vitronectin or the urokinase receptor. The protease-inhibitory actions of PAI-1 extend beyond fibrinolysis and include extracellular matrix turnover and activation of several proenzymes and latent growth factors. PAI-1 has been implicated in several renal pathogenetic processes, including thrombotic microangiopathies and proliferative and/or crescentic glomerulopathies. Most recently, it has become clear that PAI-1 also plays a pivotal role in progressive renal disease, both glomerulosclerosis and tubulointerstitial fibrosis. An active area of present research interest, untold stories are likely to be uncovered soon.
fibrinolysis; fibrosis; thrombotic microangiopathy; cellular adhesion; glomerulonephritis; renal fibrosis
![]() |
OVERVIEW |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
AN AMAZING BIOLOGICAL STORY has unfolded since an inhibitor of plasminogen activation was first isolated just a little over 20 years ago (102), and there seems to be little doubt that much remains to be learned (23, 79). Plasminogen activator inhibitor-1 (PAI-1), a member of the SERPIN (for SERine Protease INhibitor) family, is the primary physiological inhibitor of tissue-type and urokinase-type plasminogen activators (tPA and uPA, respectively). Three other molecules with PAI activity are now known: PAI-2, which may inhibit uPA in vivo; PAI-3, more correctly named protein C inhibitor to indicate its true biological action; and protease nexin-1 (156). PAI-1 is a single-chain, 50-kDa glycoprotein that exists in conformationally active and latent forms. After synthesis, active PAI-1 is rapidly secreted from most cells, with platelets the only cell type known to store quantities of latent PAI-1. Within the circulation, active PAI-1 is unstable unless it is bound to vitronectin. The primary source of active plasma PAI-1 is still unclear, but it may be hepatic. PAI-1 may also be synthesized as an acute-phase protein.
Under normal conditions, the only fibrinolytic inhibitor that is
detected in significant quantities in the kidney is
2-antiplasmin (111), although low levels of
protease nexin-1 and protein C inhibitor have been reported in mouse
mesangial cells and human tubular cells, respectively (116,
140). Not normally expressed in the kidney, PAI-1 is rapidly
induced in a variety of acute and chronic renal diseases. On the basis
of a series of in vitro and in vivo studies, it appears that PAI-1 may
be produced by several different cells within the kidney (142,
149). Several in situ hybridization studies have demonstrated
PAI-1 mRNA in diseased glomeruli and tubules and an inflamed
interstitium, but counterstaining studies with specific cellular
markers have not been performed to clearly establish the specific
identity of the PAI-1-transcribing cells. PAI-1 mRNA has been
identified in glomerular parietal epithelial cells in several
pathological states (11, 63, 88, 105, 122, 182) and in
cells presumed to be mesangial (68, 105, 122, 179),
visceral epithelial (36), and glomerular endothelial
(62, 105, 122, 132, 179). Intrarenal cells thought to be
inflammatory leukocytes (38, 62, 68, 88, 172, 182) and
renal tubules (36, 38, 39, 105, 122) may also become a
source of PAI-1. While not yet subjected to rigorous investigation, the
induction of PAI-2 and protein C inhibitor has not been documented in
diseases of the kidney. Increased expression of protease nexin-1 has
been reported in proliferative glomerulonephritis (116)
and obstructive nephropathy (78), the significance of
which remains to be established. It has been suggested that protease
nexin-1 may not function as a PAI but rather as an inhibitor of
thrombin (152).
![]() |
REGULATION OF PAI-1 EXPRESSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The synthesis of PAI-1, one of the most highly regulated
fibrinolytic components, is rapidly induced by a variety of factors. Transcriptional regulation is most important, but changes in mRNA stability may be involved in some situations (100). While
the list of reported PAI-1 agonists is impressive (Table
1), some of these effects are cell
specific, and most of these data derive from in vitro studies.
Inhibition of PAI-1 has been less extensively investigated, but
suppression has been reported with interferon-, nitric oxide,
natriuretic factors, and lipid-lowering drugs (18, 47,
56). A topic of considerable present interest originated with
the observation that plasma PAI-1 levels could be correlated with
variations in the structure of the PAI-1 gene. In particular, higher
levels are associated with a polymorphic variance in the number of
guanine bases (4G rather than 5G) at position
675 upstream of the transcription start site (93). The 5G site has been
shown to bind a transcription repressor protein, E2F (95).
Several recent studies suggest that the homozygosity for the 4G allele may be an independent risk factor for the development of
atherosclerosis and cardiovascular disease, although conflicting data
exist (93).
|
![]() |
PROTEASE INHIBITOR-DEPENDENT ACTIONS OF PAI-1 |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
PAI-1 inhibits uPA and tPA, the two known mammalian plasminogen
activators, by forming an irreversible 1:1 molar complex. PAI-1 is
consumed by this process. The noncatalytic domains of the two
plasminogen activators are very different, which likely accounts for
their distinct biological roles (Fig. 1).
The nonenzymatic domain of tPA has a high affinity for fibrin and is in
fact an inefficient activator of plasminogen in the absence of fibrin. As a consequence, tPA functions almost exclusively as a mediator of
intravascular fibrinolysis and clot dissolution. Within normal kidneys,
tPA has been identified within glomerular cells and collecting duct
epithelial cells (147).
|
In contrast, uPA does not bind to fibrin, and it is most often found at
extravascular sites, where it not only generates active plasmin but
also may cleave other substrates, including some extracellular matrix
proteins (Table 2). The noncatalytic
domain of both single-chain pro-uPA and the two-chain active protease
may bind to a specific cellular receptor, the urokinase receptor
(uPAR), also known as CD87 (168). Cellular binding
concentrates uPA and plasmin protease activity to pericellular regions.
In normal kidneys, uPA, most of which is secreted into the urine, is
produced in significant quantities by proximal tubules. However,
several cells that are recruited or activated in the kidney in response
to injury may produce uPA, including monocytes, macrophages,
fibroblasts, and myofibroblasts. The pattern of uPAR expression in
normal kidneys has not yet been carefully examined. Tubular uPAR
immunoreactivity has been reported in normal human kidneys
(170), whereas in another study in situ hybridization
failed to detect uPAR mRNA (179). In vitro studies suggest
that this receptor may be expressed by glomerular epithelial and
mesangial cells as well (127, 144). PAI-1 is often found
bound to vitronectin, an interaction that promotes the deposition of
PAI-1 within extracellular matrices and facilitates its interaction
with uPA and uPAR.
|
Plasminogen, the preferred substrate of both uPA and tPA, is primarily synthesized in the liver and circulates in a relatively high concentration in the plasma, although as much as 40% of circulating plasminogen migrates to extravascular sites (143). Plasminogen mRNA has been detected in the human kidney (112), a finding we have not been able to confirm in mouse kidneys (Eddy AA, Zhang G, Kim H, Ikeda Y, and Lopez-Guisa J, unpublished observations). Plasmin has several other possible substrates in addition to fibrin, which forms the basis for the consideration that plasmin plays an important role in extracellular matrix remodeling (Table 2).
![]() |
UNIQUE EFFECTS OF PAI-1 |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
In recent years, it has become evident the PAI-1 may influence the
behavior of several cells through activities that are independent of
its inhibitory effects on uPA and tPA activities and plasmin generation. In particular, PAI-1 modulates cellular adhesion and migration and appears to play an important role in inflammation, wound
healing, angiogenesis, and tumor cell metastasis. These activities
involve a complex interplay among PAI-1, vitronectin, uPAR, and certain
integrin receptors, with different outcomes observed depending on the
cell type and the composition of its immediate microenvironment (Fig.
1) (15, 101, 160). A key finding that appears to underlie
these effects was the recognition that PAI-1 and uPAR compete for a
common binding domain (somatomedin B) on the NH2 terminus
of vitronectin, near but distinct from the vitronectin RGD site that
binds to v
3-integrins (101). When vitronectin binds to PAI-1 (which it does with much a higher affinity than to uPAR), it not only prevents cellular adhesion between
uPAR and vitronectin-rich extracellular matrices but may also inhibit
adhesive actions between
v
3-integrins and
vitronectin by steric hindrance. In vitro at least, the
presence of PAI-1 inhibits vitronectin-dependent cellular adhesion and migration.
However, these interactions may have other consequences. Vitronectin may function as a shuttle to transfer PAI-1 to uPAR-bound uPA, with profound consequences (174). Once transferred, PAI-1 undergoes conformational changes that destroy its affinity for vitronectin and promote its degradation after endocytosis via a process that involves interactions between the uPAR-uPA-PAI-1 complex and the low-density lipoprotein receptor-related protein (LRP) (73, 94). During this latter process, PAI-1 is degraded and uPAR is recycled to the cell membrane.
On the basis of these interactions, it seems paradoxical that under
many in vivo situations the presence of PAI-1 facilitates rather than
inhibits cell migration. This is particularly true in cancer cell
biology, whereby high tumor levels of PAI-1 predict a more aggressive
metastatic phenotype (4). Recent studies in PAI-1 null
mice have confirmed this association, with significantly more
metastases observed in PAI-1 wild-type mice than in mice that are PAI-1
deficient (7). The basis of the promigratory effects of
PAI-1 are still not entirely understood. For some cells, it may be that
PAI-1 releases them from a vitronectin anchor, allowing more robust
responses involving other adhesion reactions (between
v
3-integrins and fibronectin, for
example) and chemotactic signals (81). In other
situations, the promigratory effects of PAI-1 appear coupled to an
angiogenic response (7). Here again, the molecular details
have not yet been fully dissected, but studies in genetically
engineered mice have documented a dampened angiogenic response in
PAI-1-deficient mice and a greater response in PAI-1-overexpressing
mice (109). An ex vivo study of angiogenesis also
demonstrated the importance of PAI-1, with abolition of angiogenesis in
the absence of PAI-1 (33). These recent studies suggest
that the angiogenic effects of PAI-1 are dependent on
protease-inhibitory effects rather than its interactions with
vitronectin and cellular adhesion molecules (6, 33). A
question that deserves further evaluation in vivo is whether PAI-1
promotes angiogenesis by decreasing angiostatin generation. Angiostatin
is a degradation product of plasminogen, which consists of its five
kringle domains and is released in the presence of free sulfhydryl
donors (57).
Finally, another cellular process deserving of further investigation is
the role of PAI-1 in leukocyte recruitment. Several components of the
coagulation cascade have leukocyte chemoattractant activity, including
uPA, fibrin, thrombin, and uPAR. Although a specific PAI-1 receptor has
never been reported, there is some evidence that PAI-1 may have
chemotactic effects for monocytes and fibroblasts (32,
129). Furthermore, uPAR facilitates the migration of
lymphohemopoietic cells via interactions that may involve the
selectins, 1-,
2-, or
3-integrins (26, 157). Leukocyte
recruitment was significantly reduced in uPAR-deficient mice with
pulmonary Pseudomonas aeruginosa infection
(66), and lymphocyte recruitment was depressed in an
immunologic model of pulmonary injury (67). Our laboratory
recently found that renal interstitial monocyte recruitment in response
to ureteral obstruction is also significantly attenuated in uPAR null
mice (186). Whether PAI-1 is directly involved in
uPAR-dependent recruitment of lymphohemopoietic cells is not yet clear.
Given that uPA also has chemotactic effects, PAI-1 may also block
leukocyte recruitment (32).
![]() |
PAI-1 IN ACUTE RENAL INJURY |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Thrombotic Microangiopathy
Thrombotic microangiopathy is a specific pathological entity that, within the kidney, typically involves fibrin deposition in glomerular capillaries and extraglomerular arterioles. There is now rather compelling evidence that PAI-1 plays an active role in the generation of the fibrin thrombi that are formed in response to glomerular endothelial cell injury. Glomerular PAI-1 deposition has been demonstrated in the kidneys of patients with thrombotic microangiopathy (179). Elevated plasma PAI-1 levels are reported in most studies of patients with hemolytic uremic syndrome (HUS), and the duration of the elevation has been shown to correlate with disease outcome (13, 107, 125). A recent prospective study documented that elevated plasma PAI-1 levels occur in the subset of children with Escherichia coli 0157:H7 enteric infection who develop HUS (~15%) before the onset of clinical renal disease, suggesting that PAI-1 plays an early role in the pathogenesis of the renal damage (25). With the recent characterization of better animal models of HUS, it is hoped that the specific role of PAI-1 in glomerular microvascular damage will soon be elucidated (82, 161, 165).PAI-1 has also been implicated in renal thrombotic microangiopathy
initiated by other causes of microvascular endothelial cell injury,
such as preeclampsia, endotoxemia, and radiation exposure. Elevated
plasma PAI-1 levels have been reported in women with preeclampsia
(48). Inheritance of the 4G PAI-1 allele has been
associated with an increased risk of preeclampsia (181) but not with diarrhea-associated HUS (159). Renal PAI-1
gene expression is increased in endotoxin-treated animals
(117), and treatment with PAI-1-neutralizing antibodies
significantly reduced renal fibrin deposition (118).
However, a recent study of LPS-induced renal disease in genetically
manipulated mice identified 2-antiplasmin rather than
PAI-1 as the more important regulator of renal fibrinolytic activity.
Genetic deficiency of
2-antiplasmin, but not of PAI-1, significantly reduced renal fibrin deposition (34). In an
animal model of radiation nephritis, inhibition of angiotensin
II-dependent renal PAI-1 expression significantly decreased glomerular
thrombosis and sclerosis (132).
Renal Vasculitis
Perhaps the most frequently observed glomerular pathological finding that characterizes renal vasculitis is a focal necrotizing lesion filled with fibrin. It seems reasonable to speculate that PAI-1 plays a role in the genesis of this lesion as well, although there are few human data and no reliable animal models to verify this hypothesis. PAI-1 protein has been identified together with fibrin deposits in renal biopsy specimens from patients with focal necrotizing glomerulonephritis due to systemic lupus erythematosus (68). While increased plasma levels of PAI-1 have been reported in patients with Henoch-Schonlein purpura, it is not yet clear whether this finding represents a marker of endothelial damage or a pathological feature (14). The PAI-1 4G phenotype may be a predictor of focal necrotizing lesions among patients with diffuse proliferative lupus nephritis (171).Proliferative Glomerulonephritis
The presence of PAI-1 mRNA and protein has been documented in several studies of both human and animal models of proliferative glomerulonephritis, especially those associated with fibrin deposition and crescent formation (reviewed in Ref. 142). It seems clear that inhibition of glomerular PA activity worsens the severity of glomerular injury. Mice genetically deficient in plasminogen or the combination of uPA and tPA were shown to develop more aggressive crescentic glomerulonephritis after an injection of anti-GBM antiserum, specifically, more inflammation, crescent formation, and necrosis in association with greater fibrin deposition (92). Given that tPA is considerably more abundant than uPA in glomeruli, it is perhaps not surprising that the isolated deficiency of tPA, but not uPA, resulted in glomerular injury intermediate in severity between wild-type mice and double PA-deficient mice. Treatment with recombinant tPA has been reported to decrease the extent of fibrin deposition and mesangial matrix expansion in rats with anti-Thy-1 glomerulonephritis (71).Thus far most studies infer that PAI-1 participates in the pathogenesis of acute glomerular damage by promoting fibrin accumulation. However, given the potential for PAI-1 to alter the turnover of other uPA and plasmin substrates, together with its more recently recognized protease-independent effects, it is likely that newer roles for PAI-1 in glomerular injury will be identified in the future. Because fibrin accumulation is a significant mediator of acute glomerular injury, strategies designed not only to enhance fibrinolysis, by blocking PAI-1, for example, but also to prevent fibrin formation might be therapeutic. Several anticoagulant studies performed in the 1960s and 1970s yielded conflicting results in animal models (reviewed in Ref. 44), perhaps further evidence for a multifactorial role for PAI-1. It is noteworthy that thrombin itself also has cellular receptors, protease-activated receptors (PARs). PAR-1 and PAR-2 are expressed in the kidney (16, 62, 63, 180). PAR-1-deficient mice have been shown to develop less severe crescentic glomerulonephritis than wild-type mice (31).
Membranous Nephropathy
Membranous nephropathy, a noninflammatory glomerular disease, deserves special mention even though any comment about the role of PAI-1 in disease pathogenesis is purely speculative at this time. In a PCR-based study of human kidney biopsies, PAI-1 transcripts were found to be abundant in membranous nephropathy (68). PAI-1 protein colocalizes with vitronectin, and also likely with SP40, 40 (or clusterin), within the epimembranous deposits (29, 123). It is also remarkable that the target antigen in the rat model of membranous nephropathy, megalin, is a plasminogen receptor (115). These are curious findings, the functional significance of which remains to be determined. ![]() |
PAI-1 IN PROGRESSIVE RENAL DISEASE |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
In recent years, PAI-1 has emerged as a critical mediator of
glomerulosclerosis and renal interstitial fibrosis. This has become a
particularly exciting story, because PAI-1 could be a possible
therapeutic target not only to delay progressive renal disease but also
perhaps even for disease regression, if treatment is initiated before
matrix accumulation has destroyed cellular structures within the
kidney. PAI-1 mediates several effects that may facilitate
matrix accumulation through the impairment of matrix turnover. Both uPA
and plasmin can degrade several extracellular matrix proteins (Table 2)
(reviewed in Ref. 142). While plasmin also activates
latent transforming growth factor (TGF)- in vitro (104), an undesirable effect that would enhance fibrosis,
this effect does not appear to be prominent in several in vivo studies. Plasmin also activates several latent matrix-degrading proteases, including single-chain (latent) uPA and certain latent
metalloproteinases (especially MMP-1, or collagenase-1, and MMP-3, or
stromelysin-1). In addition, uPA activates membrane type-1-MMP, which
subsequently activates MMP-2 or 72-kDa gelatinase.
While PAI-1 is essentially undetectable in normal kidneys, PAI-1 mRNA and/or protein have been found to be increased in several renal diseases associated with fibrosis, such as obstructive nephropathy (37, 129), protein-overload proteinuria (42), radiation nephropathy (20, 132), aging (105), hypertensive nephropathy (162), anti-tubular basement membrane nephritis (51, 164), nephrotoxicity (36, 80, 153, 154), lipid-induced renal injury (40), lupus nephritis (89, 167), Thy-1 nephritis (71, 166), focal segmental glomerulosclerosis (68, 184), diabetic nephropathy (183), and allograft nephropathy (155, 163, 172).
The potential importance of PAI-1 in progressive renal disease first
gained impetus with the recognition that TGF- is a critical mediator
of renal fibrosis and that TGF-
is a powerful inducer of PAI-1
expression (103). In fact, in some cells induction of PAI-1 may be its most dramatic effect. TGF-
-overexpressing mice develop progressive glomerulosclerosis in conjunction with increased PAI-1 expression (96). Studies by Baricos et al.
(10) highlight the importance of the uPA, tPA, and MMP-2
activity for mesangial cell degradation of extracellular matrix
proteins and the enhancement of this activity by PAI-1 inhibition
(10). In this in vitro experimental system, both PAI-1
production and plasminogen activation were shown to be mediated by
TGF-
(9). The case against PAI-1 was strengthened once
it became evident that a major feature of the renoprotective effect
resulting from the inhibition or absence of angiotensin II activity was
a reduction in TGF-
activity. It appears that PAI-1 expression may
be induced at several steps along this pathway (to some extent cell
dependent) by renin, angiotensin II, angiotensin IV, aldosterone, and
shear stress in addition to TGF-
-dependent induction. Several
studies based on the use of animal models performed by Border and Noble
(17) and Fogo and their respective colleagues (54,
55, 137), as well as several other laboratories, have
consolidated the link among the renin-angiotensin-aldosterone cascade,
TGF-
, and PAI-1 in the pathogenesis of glomerulosclerosis.
In the model of Thy-1 nephritis, TGF-
neutralization decreased
glomerular PAI-1 deposition and the severity of glomerulosclerosis
(166), whereas recombinant tPA therapy significantly
reduced glomerular matrix accumulation (71). Angiotensin
II can stimulate PAI-1 production both directly (90) and
indirectly via TGF-
induction (3, 177). In vivo infusion of angiotensin II increases renal PAI-1 mRNA levels, a
response that can be blocked by a selective angiotensin type I-receptor
antagonist (122). Studies in several experimental models
demonstrate that the renoprotective effects associated with
pharmacological inhibition of angiotensin II are mediated, at least in
part, by a reduction in PAI-1 expression. For example, administration
of an angiotensin-converting enzyme inhibitor or an angiotensin
receptor blocker decreased renal PAI-1 production and
glomerulosclerosis severity in rats with radiation-induced renal injury
(132). Administration of an angiotensin type 1-receptor antagonist to 18-mo-old rats not only slowed the rate of progression of
glomerulosclerosis, in association with reduced PAI-1, but also
revealed evidence of disease regression (105).
Our laboratory has extended the evidence by investigating the renal
response to injury in mice genetically deficient in PAI-1 (Fig.
2). In the model of unilateral ureteral
obstruction, the degree of interstitial fibrosis was significantly
attenuated in PAI-1 null mice (129). A similar protective
outcome was observed in the milder interstitial fibrosis model induced
by protein overload (130). These results were impressive
given our earlier studies suggesting that the single deficiency of
another protease inhibitor, the tissue inhibitor of
metalloproteinases-1 (TIMP-1), which is also dramatically upregulated
in association with interstitial fibrosis, conferred no protection
(43, 91). It is likely that high constitutive
renal levels of TIMP-2 and/or TIMP-3 compensated for the absence of
TIMP-1. These findings suggest that PAI-1 is not only an important
profibrotic protease inhibitor but also a unique and nonredundant
molecule in the kidney. In our studies, renal expression of protein C
inhibitor mRNA was never detected by Northern blot analysis. However,
protease nexin-1 mRNA expression rose in parallel with PAI-1 in the
wild-type animals and alone in the PAI-1 null mice, yet it did not
overcome the protective effects of PAI-1 deficiency (78).
These findings are consistent with the prior suggestion that protease
nexin-1 normally functions as an inhibitor of thrombin rather than PAs
(152). The other main inhibitor of fibrinolysis,
2-anti-plasmin, is produced by normal kidneys; however,
in response to ureteral obstruction, its level of expression decreased
significantly.
|
Studies in PAI-1-deficient mice have also documented less severe
bleomycin-induced lung fibrosis (45). While the first
published study associated the protective effect with decreased
pulmonary fibrin deposition, more recent studies indicate that
increased fibrin clearance does not account for the antifibrotic
effects of PAI-1 deficiency, as bleomycin-induced pulmonary fibrosis is not attenuated by a genetic deficiency of either the A- or the
-chain of fibrinogen (72, 139). Whether significant
amounts of fibrin accumulate in the renal interstitium and contribute to progressive interstitial fibrosis is a question that has not yet
been carefully investigated.
There do appear to be some fundamental differences between the protective effects of PAI-1 deficiency in the lung and the kidney. While studies in the bleomycin model indicate that increased plasmin activity is linked to the protective effects of PAI-1 deficiency, the critical substrate remains unclear (72). In our studies of ureteral obstruction, a difference in plasmin activity could not be shown between the deficient and the wild-type mice (129). This may be due to inherent limitations of the assay, and studies are in progress in plasminogen-deficient mice to clarify this issue. However, there was one other significant difference in the renal response to obstruction. The recruitment of interstitial monocytes was significantly delayed in the PAI-1-deficient mice. Because monocytes are often implicated in the fibrogenic process through numerous activities, it is quite likely that the blunting of the inflammatory response accounts, at least in part, for the antifibrotic effects of PAI-1 deficiency (41). It is not yet known whether the ability of PAI-1 to facilitate renal interstitial monocyte recruitment is a function of chemotactic or cell adhesion activities. These findings differ from the pulmonary response to bleomycin-induced injury, whereby leukocyte recruitment is apparently unaltered by PAI-1 deficiency (72).
In an effort to further investigate the role of the plasmin-protease cascade in renal fibrosis, our laboratory has recently been examining the role of uPAR. Although it is clear that uPAR is a multifunctional receptor, one of its important roles is that it is the only known pathway for elimination of PAI-1 from tissues. Despite similar levels of PAI-1 mRNA in response to ureteral obstruction, significantly more PAI-1 protein accumulated in the kidneys of the uPAR null mice, and the degree of fibrosis was more severe (186, 187). Several other differences were noted between the uPAR wild-type and -deficient mice, but it is likely that greater PAI-1 accumulation contributed to the more robust fibrogenic response observed in the absence of uPAR.
Diabetic Nephropathy
Insulin-resistant states, associated with obesity, hypertension, and diabetes, are characterized by elevated plasma PAI-1 levels (12, 93, 121). The source of this excessive PAI-1 production is likely multifactorial, but one known contributor is tumor necrosis factor-An obvious question is whether PAI-1 plays a role in the pathogenesis
of diabetic nephropathy. PAI-1 expression is increased in diabetic
nephropathic kidneys (184). The renoprotective effects of
angiotensin II inhibition have been associated with reductions in renal
TGF- expression (60, 74, 178), and TGF-
has been shown to play a role in the pathogenesis of experimental diabetic nephropathy (70, 191). While it seems reasonable to
predict from these data that PAI-1 is involved in the genesis of
diabetic nephropathy, definitive proof is not yet available. Studies in progress in our own and other laboratories are investigating whether the genetic deficiency of PAI-1 can alter the natural history of
diabetic nephropathy, but the results of these studies are not yet available.
In a Japanese population of patients with non-insulin-dependent diabetes mellitus, the presence of albuminuria has been associated with higher plasma PAI-1 levels (75). However, with one exception (171), studies have failed to identify the 4G PAI-1 allele as a risk factor for the development of diabetic nephropathy. Diabetic nephropathy is the one human disease with documented reversibility of mesangial matrix expansion, if the diabetic milieu is eliminated by successful pancreatic transplantation (52) or inadvertent transplantation of a diabetic kidney into a nondiabetic recipient (1). It would be exciting to demonstrate that turning off PAI-1 activity is involved not only in delaying progressive renal disease but also perhaps even in initiating its regression.
In summary, PAI-1, a simple 379-amino acid peptide, has emerged as an important mediator of several renal diseases, both acute and chronic. Future studies should begin to distinguish fibrinolytic and other protease-dependent and -independent effects, fundamental information that will be invaluable during the quest for new therapeutic agents. Like most biological molecules, PAI-1 likely has important beneficial effects as well. To date, only a single patient has been recognized to have a genetic deficiency of PAI-1 (50). Despite the normal phenotype of PAI-1-deficient mice (24), one has to question whether PAI-1 deficiency is really that rare, or alternatively, whether it is usually incompatible with human survival. For these reasons, as well as several others, further pursuit of PAI-1 physiology and pathophysiology seems to be a worthy endeavor.
![]() |
ACKNOWLEDGEMENTS |
---|
The author acknowledges grant support from the National Institute of Diabetes and Digestive and Kidney Diseases (DK-54500) and the Juvenile Diabetes Foundation, the support and collaboration of Dr. Jesús López-Guisa, and the work by several postdoctoral fellows and research technicians for studies from our own laboratory that were cited in this paper.
![]() |
FOOTNOTES |
---|
Address for reprint requests and other correspondence: A. Eddy, Children's Hospital and Regional Medical Ctr., Div. of Nephrology, CH-46, 4800 Sand Point Way NE, Seattle, WA 98105. (E-mail: aeddy{at}chmc.org).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
10.1152/ajprenal.00032.2002
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Abouna, GM,
Al-Adnani MS,
Kremer GD,
Kumar SA,
Daddah SK,
and
Kusma G.
Reversal of diabetic nephropathy in human cadaveric kidneys after transplantation into non-diabetic recipients.
Lancet
2:
1274-1276,
1983[Medline].
2.
Alessi, MC,
Juhan-Vague I,
Kooistra T,
Declerck PJ,
and
Collen D.
Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G.2
Thromb Haemost
60:
491-494,
1988[ISI][Medline].
3.
Anderson, PW,
Zhang XY,
Tian J,
Correale JD,
Xi XP,
Yang D,
Graf K,
Law RE,
and
Hsueh WA.
Insulin and angiotensin II are additive in stimulating TGF-beta 1 and matrix mRNAs in mesangial cells.
Kidney Int
50:
745-753,
1996[ISI][Medline].
4.
Andreasen, PA,
Kjoller L,
Christensen L,
and
Duffy MJ.
The urokinase-type plasminogen activator system in cancer metastasis: a review.
Int J Cancer
72:
1-22,
1997[ISI][Medline].
5.
Aplin, JD,
and
Hughes RC.
Complex carbohydrates of the extracellular matrix structures, interactions and biological roles.
Biochim Biophys Acta
694:
375-418,
1982[ISI][Medline].
6.
Bajou, K,
Masson V,
Gerard RD,
Schmitt PM,
Albert V,
Praus M,
Lund LR,
Frandsen TL,
Brunner N,
Dano K,
Fusenig NE,
Weidle U,
Carmeliet G,
Loskutoff D,
Collen D,
Carmeliet P,
Foidart JM,
and
Noel A.
The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies.
J Cell Biol
152:
777-784,
2001
7.
Bajou, K,
Noel A,
Gerard RD,
Masson V,
Brunner N,
Holst-Hansen C,
Skobe M,
Fusenig NE,
Carmeliet P,
Collen D,
and
Foidart JM.
Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization.
Nat Med
4:
923-928,
1998[ISI][Medline].
8.
Banfi, C,
Eriksson P,
Giandomenico G,
Mussoni L,
Sironi L,
Hamsten A,
and
Tremoli E.
Transcriptional regulation of plasminogen activator inhibitor type 1 gene by insulin: insights into the signaling pathway.
Diabetes
50:
1522-1530,
2001
9.
Baricos, WH,
Cortez SL,
Deboisblanc M,
and
Xin S.
Transforming growth factor-beta is a potent inhibitor of extracellular matrix degradation by cultured human mesangial cells.
J Am Soc Nephrol
10:
790-795,
1999
10.
Baricos, WH,
Cortez SL,
El-Dahr S,
and
Schnaper HW.
ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade.
Kidney Int
47:
1039-1047,
1995[ISI][Medline].
11.
Barnes, JL,
Mitchell RJ,
and
Torres ES.
Expression of plasminogen activator-inhibitor-1 (PAI-1) during cellular remodeling in proliferative glomerulonephritis in the rat.
J Histochem Cytochem
43:
895-905,
1995
12.
Bastard, JP,
Pieroni L,
and
Hainque B.
Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance.
Diabetes Metab Res Rev
16:
192-201,
2000[ISI][Medline].
13.
Bergstein, JM,
Riley M,
and
Bang NU.
Role of plasminogen-activator inhibitor type 1 in the pathogenesis and outcome of the hemolytic uremic syndrome.
N Engl J Med
327:
755-759,
1992[Abstract].
14.
Besbas, N,
Erbay A,
Saatci U,
Ozdemir S,
Bakkaloglu A,
Ozen S,
and
Topaloglu R.
Thrombomodulin, tissue plasminogen activator and plasminogen activator inhibitor-1 in Henoch-Schonlein purpura.
Clin Exp Rheumatol
16:
95-98,
1998[ISI][Medline].
15.
Blasi, F.
uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive, and chemotactic highways?
Immunol Today
18:
415-417,
1997[ISI][Medline].
16.
Bohm, SK,
Kong W,
Bromme D,
Smeekens SP,
Anderson DC,
Connolly A,
Kahn M,
Nelken NA,
Coughlin SR,
Payan DG,
and
Bunnett NW.
Molecular cloning, expression and potential functions of the human proteinase-activated receptor-2.
Biochem J
314:
1009-1016,
1996[ISI][Medline].
17.
Border, WA,
and
Noble NA.
Transforming growth factor in tissue fibrosis.
N Engl J Med
331:
1286-1292,
1994
18.
Bouchie, JL,
Hansen H,
and
Feener EP.
Natriuretic factors and nitric oxide suppress plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Role of cGMP in the regulation of the plasminogen system.
Arterioscler Thromb Vasc Biol
18:
1771-1779,
1998
19.
Brown, NJ,
Kim KS,
Chen YQ,
Blevins LS,
Nadeau JH,
Meranze SG,
and
Vaughan DE.
Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production.
J Clin Endocrinol Metab
85:
336-344,
2000
20.
Brown, NJ,
Nakamura S,
Ma L,
Nakamura I,
Donnert E,
Freeman M,
Vaughan DE,
and
Fogo AB.
Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo.
Kidney Int
58:
1219-1227,
2000[ISI][Medline].
21.
Camiolo, SM,
Thorsen S,
and
Astrup T.
Fibrinogenolysis and fibrinolysis with tissue plasminogen activator, urokinase, streptokinase-activated human globulin, and plasmin.
Proc Soc Exp Biol Med
138:
277-280,
1971.
22.
Carmassi, F,
Morale M,
Ferrini L,
Dell'Omo G,
Ferdeghini M,
Pedrinelli R,
and
De Negri F.
Local insulin infusion stimulates expression of plasminogen activator inhibitor-1 and tissue-type plasminogen activator in normal subjects.
Am J Med
107:
344-350,
1999[ISI][Medline].
23.
Carmeliet, P,
and
Collen D.
Development and disease in proteinase-deficient mice: role of the plasminogen, matrix metalloproteinase and coagulation system.
Thromb Res
91:
255-285,
1998[ISI][Medline].
24.
Carmeliet, P,
Kieckens L,
Schoonjans L,
Ream B,
Van Nuffelen A,
Prendergast G,
Cole M,
Bronson R,
Collen D,
and
Mulligan RC.
Plasminogen activator inhibitor-1 gene-deficient mice. 1. Generation by homologous recombination and characterization.
J Clin Invest
92:
2746-2755,
1993[ISI][Medline].
25.
Chandler, W,
Jelacic S,
Boster D,
Ciol M,
Williams G,
Watkins S,
Igarashi T,
and
Tarr P.
Prothrombotic coagulation abnormalities during Escherichia coli 0157:H.7 infections.
N Engl J Med
346:
23-32,
2002
26.
Chapman, HA,
and
Wei Y.
Protease crosstalk with integrins: the urokinase receptor paradigm.
Thromb Haemost
86:
124-129,
2001[ISI][Medline].
27.
Chen, YQ,
Su M,
Walia RR,
Hao Q,
Covington JW,
and
Vaughan DE.
Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells.
J Biol Chem
273:
8225-8231,
1998
28.
Cheng, JJ,
Chao YJ,
Wung BS,
and
Wang DL.
Cyclic strain-induced plasminogen activator inhibitor-1 (PAI-1) release from endothelial cells involves reactive oxygen species.
Biochem Biophys Res Commun
225:
100-105,
1996[ISI][Medline].
29.
Choi-Miura, N.
SP40, 40 is a component of plasminogen activator inhibitor-1-binding protein, and stabilizes plasminogen activator inhibitor-1 activity.
Biol Pharm Bull
24:
39-42,
2001[ISI][Medline].
30.
Coligan, JE,
and
Slayter HS.
Structure of thrombospondin.
J Biol Chem
259:
3944-3948,
1984
31.
Cunningham, MA,
Rondeau E,
Chen X,
Coughlin SR,
Holdsworth SR,
and
Tipping PG.
Protease-activated receptor 1 mediates thrombin-dependent, cell-mediated renal inflammation in crescentic glomerulonephritis.
J Exp Med
191:
455-462,
2000
32.
Degryse, B,
Sier CF,
Resnati M,
Conese M,
and
Blasi F.
PAI-1 inhibits urokinase-induced chemotaxis by internalizing the urokinase receptor.
FEBS Lett
505:
249-254,
2001[ISI][Medline].
33.
Devy, L,
Blacher S,
Grignet-Debrus C,
Bajou K,
Masson V,
Gerard RD,
Gils A,
Carmeliet G,
Carmeliet P,
Declerck PJ,
Noel A,
and
Foidart JM.
The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent.
FASEB J
16:
147-154,
2002
34.
Dewerchin, M,
Collen D,
and
Lijnen HR.
Enhanced fibrinolytic potential in mice with combined homozygous deficiency of alpha2-antiplasmin and PAI-1.
Thromb Haemost
86:
640-646,
2001[ISI][Medline].
35.
Dichtl, W,
Stiko A,
Eriksson P,
Goncalves I,
Calara F,
Banfi C,
Ares MP,
Hamsten A,
and
Nilsson J.
Oxidized LDL and lysophosphatidylcholine stimulate plasminogen activator inhibitor-1 expression in vascular smooth muscle cells.
Arterioscler Thromb Vasc Biol
19:
3025-3032,
1999
36.
Duymelinck, C,
Dauwe SE,
Nouwen EJ,
DeBroe ME,
and
Verpooten GA.
Cholesterol feeding accentuates the cyclosporine-induced elevation of renal plasminogen activator inhibitor type I.
Kidney Int
51:
1818-1830,
1997[ISI][Medline].
37.
Duymelinck, C,
Dauwe SEH,
De Greef KEJ,
Ysebaert DK,
Verpooten GA,
and
De Broe ME.
TIMP1 gene expression and PAI-1 antigen after unilateral ureteral obstruction in the adult male rat.
Kidney Int
58:
1186-1201,
2000[ISI][Medline].
38.
Duymelinck, C,
Deng JT,
Dauwe SE,
DeBroe ME,
and
Verpooten GA.
Inhibition of the matrix metalloproteinase system in a rat model of chronic cyclosporine nephropathy.
Kidney Int
54:
804-818,
1998[ISI][Medline].
39.
Eddy, AA.
Expression of genes that promote renal interstitial fibrosis in rats with proteinuria.
Kidney Int
49:
S49-S54,
1996[ISI].
40.
Eddy, AA.
Interstitial inflammation, and fibrosis in rats with diet-induced hypercholesterolemia.
Kidney Int
50:
1139-1149,
1996[ISI][Medline].
41.
Eddy, AA.
Role of cellular infiltrates in response to proteinuria.
Am J Kidney Dis
37, Suppl2:
525-529,
2001.
42.
Eddy, AA,
and
Giachelli CM.
Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria.
Kidney Int
47:
1546-1557,
1995[ISI][Medline].
43.
Eddy, AA,
Kim H,
Lopez-Guisa J,
Oda T,
and
Soloway PD.
Interstitial fibrosis in mice with overload proteinuria: deficiency of TIMP-1 is not protective.
Kidney Int
58:
618-628,
2000[ISI][Medline].
44.
Eddy, AA,
and
Michael AF.
Immunological mechanisms of renal injury. In: Pediatric Kidney Disease (2nd ed.), edited by Edelmann CM, Jr.. Boston: MA: Little, Brown, 1992, p. 329-397.
45.
Eitzman, DT,
McCoy RD,
Zheng X,
Fay WP,
Shen T,
Ginsburg D,
and
Simon RH.
Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene.
J Clin Invest
97:
232-237,
1996
46.
Emeis, JJ,
and
Kooistra T.
Interleukin 1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells.
J Exp Med
163:
1260-1266,
1986[Abstract].
47.
Essig, M,
Vrtovsnik F,
Nguyen G,
Sraer JD,
and
Friedlander G.
Lovastatin modulates in vivo and in vitro the plasminogen activator/plasmin system of rat proximal tubular cells: role of geranylgeranylation and Rho proteins.
J Am Soc Nephrol
9:
1377-1388,
1998[Abstract].
48.
Estelles, A,
Gilabert J,
Grancha S,
Yamamoto K,
Thinnes T,
Espana F,
Aznar J,
and
Loskutoff DJ.
Abnormal expression of type 1 plasminogen activator inhibitor and tissue factor in severe preeclampsia.
Thromb Haemost
79:
500-508,
1998[ISI][Medline].
49.
Etingin, OR,
Hajjar DP,
Hajjar KA,
Harpel PC,
and
Nachman RL.
Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis.
J Biol Chem
266:
2459-2465,
1991
50.
Fay, WP,
Shapiro AD,
Shih JL,
Schleef RR,
and
Ginsburg D.
Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation.
N Engl J Med
327:
1729-1733,
1992[ISI][Medline].
51.
Feng, L,
Tang WW,
Loskutoff DJ,
and
Wilson CB.
Dysfunction of glomerular fibrinolysis in experimental antiglomerular basement membrane antibody glomerulonephritis.
J Am Soc Nephrol
3:
1753-1764,
1993[Abstract].
52.
Fioretto, P,
Steffes MW,
Sutherland DE,
Goetz FC,
and
Mauer M.
Reversal of lesions of diabetic nephropathy after pancreas transplantation.
N Engl J Med
339:
69-75,
1998
53.
Fisher, EJ,
McLennan SV,
Yue DK,
and
Turtle JR.
High glucose reduces generation of plasmin activity by mesangial cells.
Microvasc Res
53:
173-178,
1997[ISI][Medline].
54.
Fogo, AB.
The role of angiotensin II, and plasminogen activator inhibitor-1 in progressive glomerulosclerosis.
Am J Kidney Dis
35:
179-188,
2000[ISI][Medline].
55.
Fogo, AB.
Progression, and potential regression of glomerulosclerosis.
Kidney Int
59:
804-819,
2001[ISI][Medline].
56.
Gallicchio, M,
Hufnagl P,
Wojta J,
and
Tipping P.
IFNgamma inhibits thrombin- and endotoxin-induced plasminogen activator inhibitor type 1 in human endothelial cells.
J Immunol
157:
2610-2617,
1996[Abstract].
57.
Gately, S,
Twardowski P,
Stack MS,
Cundiff DL,
Grella D,
Castellino FJ,
Enghild J,
Kwaan HC,
Lee F,
Kramer RA,
Volpert O,
Bouck N,
and
Soff GA.
The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin.
Proc Natl Acad Sci USA
94:
10868-10872,
1997
58.
Gelehrter, TD,
and
Sznycer-Laszuk R.
Thrombin induction of plasminogen activator-inhibitor in cultured human endothelial cells.
J Clin Invest
77:
165-169,
1986[ISI][Medline].
59.
Gesualdo, L,
Ranieri E,
Monno R,
Rossiello MR,
Colucci M,
Semeraro N,
Grandaliano G,
Schena FP,
Ursi M,
and
Cerullo G.
Angiotensin IV stimulates plasminogen activator inhibitor-1 expression in proximal tubular epithelial cells.
Kidney Int
56:
461-470,
1999[ISI][Medline].
60.
Gilbert, RE,
Cox A,
Wu LL,
Allen TJ,
Hulthen UL,
Jerums G,
and
Cooper ME.
Expression of transforming growth factor-beta1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition.
Diabetes
47:
414-422,
1998[Abstract].
61.
Gold, LI,
Schwimmer R,
and
Quigley JP.
Human plasma fibronectin as a substrate for human urokinase.
Biochem J
262:
529-534,
1989[ISI][Medline].
62.
Grandaliano, G,
Di Paolo S,
Monno R,
Stallone G,
Ranieri E,
Pontrelli P,
Gesualdo L,
and
Schena FP.
Protease-activated receptor 1 and plasminogen activator inhibitor 1 expression in chronic allograft nephropathy: the role of coagulation and fibrinolysis in renal graft fibrosis 1.
Transplantation
72:
1437-1443,
2001[ISI][Medline].
63.
Grandaliano, G,
Gesualdo L,
Ranieri E,
Monno R,
and
Schena FP.
Tissue factor, plasminogen activator inhibitor-1, and thrombin receptor expression in human crescentic glomerulonephritis.
Am J Kidney Dis
35:
726-738,
2000[ISI][Medline].
64.
Gundersen, D,
Tran-Thang C,
Sordat B,
Mourali F,
and
Ruegg C.
Plasmin-induced proteolysis of tenascin-C: modulation by T lymphocyte-derived urokinase-type plasminogen activator and effect on T lymphocyte adhesion, activation, and cell clustering.
J Immunol
158:
1051-1060,
1997[Abstract].
65.
Gurewich, V,
Pannell R,
Louie S,
Kelley P,
Suddith RL,
and
Greenlee R.
Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species.
J Clin Invest
73:
1731-1739,
1984[ISI][Medline].
66.
Gyetko, MR,
Sud S,
Kendall T,
Fuller JA,
Newstead MW,
and
Standiford TJ.
Urokinase receptor-deficient mice have impaired neutrophil recruitment in response to pulmonary Pseudomonas aeruginosa infection.
J Immunol
165:
1513-1519,
2000
67.
Gyetko, MR,
Sud S,
Sonstein J,
Polak T,
Sud A,
and
Curtis JL.
Cutting edge: antigen-driven lymphocyte recruitment to the lung is diminished in the absence of urokinase-type plasminogen activator (uPA) receptor, but is independent of uPA.
J Immunol
167:
5539-5542,
2001
68.
Hamano, K,
Iwano M,
Akai Y,
Sato H,
Kubo A,
Nishitani Y,
Uyama H,
Yoshida Y,
Miyazaki M,
Shiiki H,
Kohno S,
and
Dohi K.
Expression of glomerular plasminogen activator inhibitor type 1 in glomerulonephritis.
Am J Kidney Dis
39:
695-705,
2002[ISI][Medline].
69.
Hamilton, JA,
Whitty GA,
Stanton H,
Wojta J,
Gallichio M,
McGrath K,
and
Ianches G.
Macrophage colony-stimulating factor and granulocyte-macrophage colony-stimulating factor stimulate the synthesis of plasminogen-activator inhibitors by human monocytes.
Blood
82:
3616-3621,
1993[Abstract].
70.
Han, DC,
Hoffman BB,
Hong SW,
Guo J,
and
Ziyadeh FN.
Therapy with antisense TGF-1 oligodeoxynucleotides reduces kidney weight and matrix mRNAs in diabetic mice.
Am J Physiol Renal Physiol
278:
F628-F634,
2000
71.
Haraguchi, M,
Border WA,
Huang Y,
and
Noble NA.
t-PA promotes glomerular plasmin generation and matrix degradation in experimental glomerulonephritis.
Kidney Int
59:
2146-2155,
2001[ISI][Medline].
72.
Hattori, N,
Degen JL,
Sisson TH,
Liu H,
Moore BB,
Pandrangi RG,
Simon RH,
and
Drew AF.
Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice.
J Clin Invest
106:
1341-1350,
2000
73.
Herz, J,
and
Strickland D.
LRP: a multifunctional scavenger and signaling receptor.
J Clin Invest
108:
779-784,
2001
74.
Hill, C,
Logan A,
Smith C,
Gronbaek H,
and
Flyvbjerg A.
Angiotensin converting enzyme inhibitor suppresses glomerular transforming growth factor beta receptor expression in experimental diabetes in rats.
Diabetologia
44:
495-500,
2001[ISI][Medline].
75.
Hirano, T,
Kashiwazaki K,
Moritomo Y,
Nagano S,
and
Adachi M.
Albuminuria is directly associated with increased plasma PAI-1 and factor VII levels in NIDDM patients.
Diabetes Res Clin Pract
36:
11-18,
1997[ISI][Medline].
76.
Hopkins, WE,
Westerhausen DR, Jr,
Sobel BE,
and
Billadello JJ.
Transcriptional regulation of plasminogen activator inhibitor type-1 mRNA in Hep G2 cells by epidermal growth factor.
Nucleic Acids Res
19:
163-168,
1991[Abstract].
77.
Horton, MR,
Olman MA,
Bao C,
White KE,
Choi AM,
Chin BY,
Noble PW,
and
Lowenstein CJ.
Regulation of plasminogen activator inhibitor-1 and urokinase by hyaluronan fragments in mouse macrophages.
Am J Physiol Lung Cell Mol Physiol
279:
L707-L715,
2000
78.
Ikeda, Y,
Jung Y,
Oda T,
Cai X,
Lopez-Guisa J,
and
Eddy A.
Increased expression of protease nexin-1 during renal fibrosis (Abstract).
J Am Soc Nephrol
12:
722,
2001.
79.
Irigoyen, JP,
Munoz-Canoves P,
Montero L,
Koziczak M,
and
Nagamine Y.
The plasminogen activator system: biology and regulation.
Cell Mol Life Sci
56:
104-132,
1999[ISI][Medline].
80.
Islam, M,
Burke JF, Jr,
McGowan TA,
Zhu Y,
Dunn SR,
McCue P,
Kanalas J,
and
Sharma K.
Effect of anti-transforming growth factor-beta antibodies in cyclosporine-induced renal dysfunction.
Kidney Int
59:
498-506,
2001[ISI][Medline].
81.
Isogai, C,
Laug WE,
Shimada H,
Declerck PJ,
Stins MF,
Durden DL,
Erdreich-Epstein A,
and
DeClerck YA.
Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin.
Cancer Res
61:
5587-5594,
2001
82.
Isogai, E,
Isogai H,
Kimura K,
Hayashi S,
Kubota T,
Fujii N,
and
Takeshi K.
Role of tumor necrosis factor alpha in gnotobiotic mice infected with an Escherichia coli O157:H7 strain.
Infect Immun
66:
197-202,
1998
83.
James, LR,
Fantus IG,
Goldberg H,
Ly H,
and
Scholey JW.
Overexpression of GFAT activates PAI1 promoter in mesangial cells.
Am J Physiol Renal Physiol
279:
F718-F727,
2000
84.
Kagami, S,
Kuhara T,
Okada K,
Kuroda Y,
Border WA,
and
Noble NA.
Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells.
Kidney Int
51:
664-671,
1997[ISI][Medline].
85.
Kaikita, K,
Fogo AB,
Ma L,
Schoenhard JA,
Brown NJ,
and
Vaughan DE.
Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition.
Circulation
104:
839-844,
2001
86.
Kasai, S,
Arimura H,
Nishida M,
and
Suyama T.
Primary structure of single-chain pro-urokinase.
J Biol Chem
260:
12382-12389,
1985
87.
Kazes, I,
Delarue F,
Hagege J,
Bouzhir-Sima L,
Rondeau E,
Sraer JD,
and
Nguyen G.
Soluble latent membrane-type 1 matrix metalloprotease secreted by human mesangial cells is activated by urokinase.
Kidney Int
54:
1976-1984,
1998[ISI][Medline].
88.
Keeton, M,
Ahn C,
Eguchi Y,
Burlingame R,
and
Loskutoff DJ.
Expression of type 1 plasminogen activator inhibitor in renal tissue in murine lupus nephritis.
Kidney Int
47:
148-157,
1995[ISI][Medline].
89.
Keeton, M,
Eguchi Y,
Sawdey M,
Ahn C,
and
Loskutoff DJ.
Cellular localization of type 1 plasminogen activator inhibitor messenger RNA and protein in murine renal tissue.
Am J Pathol
142:
59-70,
1993[Abstract].
90.
Kerins, DM,
Hao Q,
and
Vaughan DE.
Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV.
J Clin Invest
96:
2515-2520,
1995[ISI][Medline].
91.
Kim, H,
Oda T,
Lopez-Guisa J,
Wing D,
Edwards DR,
Soloway PD,
and
Eddy AA.
TIMP1 deficiency does not attenuate interstitial fibrosis in obstructive nephropathy.
J Am Soc Nephrol
12:
736-748,
2001
92.
Kitching, AR,
Holdsworth SR,
Ploplis VA,
Plow EF,
Collen D,
Carmeliet P,
and
Tipping PG.
Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis.
J Exp Med
185:
963-968,
1997
93.
Kohler, HP,
and
Grant PJ.
Plasminogen-activator inhibitor type 1 and coronary artery disease.
N Engl J Med
342:
1792-1801,
2000
94.
Kounnas, MZ,
Henkin J,
Argraves WS,
and
Strickland DK.
Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor mediates cellular uptake of pro-urokinase.
J Biol Chem
268:
21862-21867,
1993
95.
Koziczak, M,
Muller H,
Helin K,
and
Nagamine Y.
E2F1-mediated transcriptional inhibition of the plasminogen activator inhibitor type 1 gene.
Eur J Biochem
268:
4969-4978,
2001
96.
Krag, S,
Osterby R,
Chai Q,
Nielsen CB,
Hermans C,
and
Wogensen L.
TGFbeta1-induced glomerular disorder is associated with impaired concentrating ability mimicking primary glomerular disease with renal failure in man.
Lab Invest
80:
1855-1868,
2000[ISI][Medline].
97.
Lane, TF,
Iruela-Arispe ML,
and
Sage EH.
Regulation of gene expression by SPARC during angiogenesis in vitro. Changes in fibronectin, thrombospondin-1, and plasminogen activator inhibitor-1.
J Biol Chem
267:
16736-16745,
1992
98.
Le Magueresse-Battistoni, B,
Pernod G,
Kolodie L,
Morera AM,
and
Benahmed M.
Tumor necrosis factor-alpha regulates plasminogen activator inhibitor-1 in rat testicular peritubular cells.
Endocrinology
138:
1097-1105,
1997
99.
Longstaff, C,
Clough AM,
and
Gaffney PJ.
Kinetics of plasmin activation of single chain urinary-type plasminogen activator (scu-PA) and demonstration of a high affinity interaction between scu-PA and plasminogen.
J Biol Chem
267:
173-179,
1992
100.
Loskutoff, D.
Regulation of PAI1 gene expression.
Fibrinolysis
5:
197-206,
1991[ISI].
101.
Loskutoff, DJ,
Curriden SA,
Hu G,
and
Deng G.
Regulation of cell adhesion by PAI-1.
APMIS
107:
54-61,
1999[ISI][Medline].
102.
Loskutoff, DJ,
and
Edgington TS.
An inhibitor of plasminogen activator in rabbit endothelial cells.
J Biol Chem
256:
4142-4145,
1981
103.
Lund, LR,
Riccio A,
Andreasen PA,
Nielsen LS,
Kristensen P,
Laiho M,
Saksela O,
Blasi F,
and
Dano K.
Transforming growth factor-beta is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts.
Embo J
6:
1281-1286,
1987[Abstract].
104.
Lyons, RM,
Gentry LE,
Purchio AF,
and
Moses HL.
Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin.
J Cell Biol
110:
1361-1367,
1990[Abstract].
105.
Ma, LJ,
Nakamura S,
Whitsitt JS,
Marcantoni C,
Davidson JM,
and
Fogo AB.
Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1.
Kidney Int
58:
2425-2436,
2000[ISI][Medline].
106.
Marder, VJ,
and
Sherry S.
Thrombolytic therapy: current status.
N Engl J Med
318:
1512-1520,
1988[ISI][Medline].
107.
Martin, AA,
Woolven BL,
Harris SJ,
Keeley SR,
Adams LD,
Jureidini KF,
and
Henning PH.
Plasminogen activator inhibitor type-1 and interleukin-6 in haemolytic uraemic syndrome.
J Paediatr Child Health
36:
327-331,
2000[ISI][Medline].
108.
Mayer, U,
Mann K,
Timpl R,
and
Murphy G.
Sites of nidogen cleavage by proteases involved in tissue homeostasis and remodelling.
Eur J Biochem
217:
877-884,
1993[Abstract].
109.
McMahon, GA,
Petitclerc E,
Stefansson S,
Smith E,
Wong MK,
Westrick RJ,
Ginsburg D,
Brooks PC,
and
Lawrence DA.
Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis.
J Biol Chem
276:
33964-33968,
2001
110.
Medcalf, RL,
Van den Berg E,
and
Schleuning WD.
Glucocorticoid-modulated gene expression of tissue- and urinary-type plasminogen activator and plasminogen activator inhibitor 1 and 2.
J Cell Biol
106:
971-978,
1988[Abstract].
111.
Menoud, PA,
Sappino N,
Boudal-Khoshbeen M,
Vassalli JD,
and
Sappino AP.
The kidney is a major site of 2-antiplasmin production.
J Clin Invest
97:
2478-2484,
1996
112.
Meroni, G,
Buraggi G,
Mantovani R,
and
Taramelli R.
Motifs resembling hepatocyte nuclear factor 1 and activator protein 3 mediate the tissue specificity of the human plasminogen gene.
Eur J Biochem
236:
373-382,
1996[Abstract].
113.
Midorikawa, S,
Sanada H,
Hashimoto S,
and
Watanabe T.
Enhancement by homocysteine of plasminogen activator inhibitor-1 gene expression and secretion from vascular endothelial and smooth muscle cells.
Biochem Biophys Res Commun
272:
182-185,
2000[ISI][Medline].
114.
Mignatti, P,
and
Rifkin DB.
Biology and biochemistry of proteinases in tumor invasion.
Physiol Rev
73:
161-195,
1993
115.
Moestrup, SK,
Nielsen S,
Andreasen P,
Jorgensen KE,
Nykjaer A,
Roigaard H,
Gliemann J,
and
Christensen EI.
Epithelial glycoprotein-330 mediates endocytosis of plasminogen activator-plasminogen activator inhibitor type-1 complexes.
J Biol Chem
268:
16564-16570,
1993
116.
Moll, S,
Schaeren-Wiemers N,
Wohlwend A,
Pastore Y,
Fulpius T,
Monard D,
Sappino AP,
Schifferli JA,
Vassalli JD,
and
Izui S.
Protease nexin 1 in the murine kidney: glomerular localization and up-regulation in glomerulopathies.
Kidney Int
50:
1936-1945,
1996[ISI][Medline].
117.
Moll, S,
Schifferli JA,
Huarte J,
Lemoine R,
Vassalli JD,
and
Sappino AP.
LPS induces major changes in the extracellular proteolytic balance in the murine kidney.
Kidney Int
45:
500-508,
1994[ISI][Medline].
118.
Montes, R,
Declerck PJ,
Calvo A,
Montes M,
Hermida J,
Munoz MC,
and
Rocha E.
Prevention of renal fibrin deposition in endotoxin-induced DIC through inhibition of PAI-1.
Thromb Haemost
84:
65-70,
2000[ISI][Medline].
119.
Nagai, T,
Akizawa T,
Kohjiro S,
Koiwa F,
Nabeshima K,
Niikura K,
Kino K,
Kanamori N,
Kinugasa E,
and
Ideura T.
rHuEPO enhances the production of plasminogen activator inhibitor-1 in cultured endothelial cells.
Kidney Int
50:
102-107,
1996[ISI][Medline].
120.
Nagase, H.
Activation mechanisms of matrix metalloproteinases.
Biol Chem
378:
151-160,
1997[ISI][Medline].
121.
Nagi, DK,
McCormack LJ,
Mohamed-Ali V,
Yudkin JS,
Knowler WC,
and
Grant PJ.
Diabetic retinopathy, promoter (4G/5G) polymorphism of PAI1 gene, and PAI1 activity in Pima Indians with type 2 diabetes.
Diabetes Care
20:
1304-1309,
1997[Abstract].
122.
Nakamura, S,
Nakamura I,
Ma L,
Vaughan DE,
and
Fogo AB.
Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo.
Kidney Int
58:
251-259,
2000[ISI][Medline].
123.
Nakamura, T,
Tanaka N,
Higuma N,
Kazama T,
Kobayashi I,
and
Yokota S.
The localization of plasminogen activator inhibitor-1 in glomerular subepithelial deposits in membranous nephropathy.
J Am Soc Nephrol
7:
2434-2444,
1996[Abstract].
124.
Naldini, L,
Vigna E,
Bardelli A,
Follenzi A,
Galimi F,
and
Comoglio PM.
Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction.
J Biol Chem
270:
603-611,
1995
125.
Nevard, CH,
Jurd KM,
Lane DA,
Philippou H,
Haycock GB,
and
Hunt BJ.
Activation of coagulation and fibrinolysis in childhood diarrhoea-associated haemolytic uraemic syndrome.
Thromb Haemost
78:
1450-1455,
1997[ISI][Medline].
126.
Nguyen, G,
Delarue F,
Berrou J,
Rondeau E,
and
Sraer JD.
Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1 antigen.
Kidney Int
50:
1897-1903,
1996[ISI][Medline].
127.
Nguyen, G,
Li XM,
Peraldi MN,
Zacharias U,
Hagège J,
Rondeau E,
and
Sraer JD.
Receptor binding and degradation of urokinase-type plasminogen activator by human mesangial cells.
Kidney Int
46:
208-215,
1994[ISI][Medline].
128.
Nordt, TK,
Klassen KJ,
Schneider DJ,
and
Sobel BE.
Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis.
Arterioscler Thromb
13:
1822-1828,
1993[Abstract].
129.
Oda, T,
Jung YO,
Kim H,
Cai X,
Lopez-Guisa J,
Ikeda Y,
and
Eddy AA.
PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction.
Kidney Int
30:
587-596,
2001.
130.
Oda, T,
Kim H,
Wing D,
López-Guisa J,
Jernigan S,
and
Eddy AA.
Effects of genetic PAI-1 deficiency in mice with protein-overload proteinuria (Abstract).
J Am Soc Nephrol
10:
578,
1999.
131.
Odekon, LE,
Sato Y,
and
Rifkin DB.
Urokinase-type plasminogen activator mediates basic fibroblast growth factor-induced bovine endothelial cell migration independent of its proteolytic activity.
J Cell Physiol
150:
258-263,
1992[ISI][Medline].
132.
Oikawa, T,
Freeman M,
Lo W,
Vaughan DE,
and
Fogo A.
Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition.
Kidney Int
51:
164-172,
1997[ISI][Medline].
133.
Olman, MA,
Hagood JS,
Simmons WL,
Fuller GM,
Vinson C,
and
White KE.
Fibrin fragment induction of plasminogen activator inhibitor transcription is mediated by activator protein-1 through a highly conserved element.
Blood
94:
2029-2038,
1999
134.
Olofsson, B,
Korpelainen E,
Pepper MS,
Mandriota SJ,
Aase K,
Kumar V,
Gunji Y,
Jeltsch MM,
Shibuya M,
Alitalo K,
and
Eriksson U.
Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells.
Proc Natl Acad Sci USA
95:
11709-11714,
1998
135.
Ott, U,
Odermatt E,
Engel J,
Furthmayr H,
and
Timpl R.
Protease resistance and conformation of laminin.
Eur J Biochem
123:
63-72,
1982[ISI][Medline].
136.
Park, JE,
Keller GA,
and
Ferrara N.
The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF.
Mol Biol Cell
4:
1317-1326,
1993[Abstract].
137.
Peters, H,
Border WA,
and
Noble NA.
Angiotensin II blockade and low-protein diet produce additive therapeutic effects in experimental glomerulonephritis.
Kidney Int
57:
1493-1501,
2000[ISI][Medline].
138.
Pinsky, DJ,
Liao H,
Lawson CA,
Yan SF,
Chen J,
Carmeliet P,
Loskutoff DJ,
and
Stern DM.
Coordinated induction of plasminogen activator inhibitor-1 (PAI-1) and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular fibrin deposition.
J Clin Invest
102:
919-928,
1998
139.
Ploplis, VA,
Wilberding J,
McLennan L,
Liang Z,
Cornelissen I,
DeFord ME,
Rosen ED,
and
Castellino FJ.
A total fibrinogen deficiency is compatible with the development of pulmonary fibrosis in mice.
Am J Pathol
157:
703-708,
2000
140.
Radtke, KP,
Fern'andez JA,
Greengard JS,
Tang WW,
Wilson CB,
Loskutoff DJ,
Scharrer I,
and
Griffin JH.
Protein C inhibitor is expressed in tubular cells of human kidney.
J Clin Invest
94:
2117-2124,
1994[ISI][Medline].
141.
Reilly, TM,
Greenplate G,
and
Timmermans PB.
Tissue plasminogen activator-induced secretion of type-1 plasminogen activator inhibitor in cultured human fibroblasts.
Thromb Res
55:
619-625,
1989[ISI][Medline].
142.
Rerolle, JP,
Hertig A,
Nguyen G,
Sraer JD,
and
Rondeau E.
Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis.
Kidney Int
58:
1841-1850,
2000[ISI][Medline].
143.
Romer, J,
Bugge TH,
Pyke C,
Lund LR,
Flick MJ,
Degen JL,
and
Dano K.
Impaired wound healing in mice with a disrupted plasminogen gene.
Nature Med
2:
287-292,
1996[ISI][Medline].
144.
Rondeau, E,
Ochi S,
Lacave R,
He CJ,
Medcalf R,
Delarue F,
and
Sraer JD.
Urokinase synthesis and binding by glomerular epithelial cells in culture.
Kidney Int
36:
593-600,
1989[ISI][Medline].
145.
Saksela, O,
Moscatelli D,
and
Rifkin DB.
The opposing effects of basic fibroblast growth factor and transforming growth factor beta on the regulation of plasminogen activator activity in capillary endothelial cells.
J Cell Biol
105:
957-963,
1987[Abstract].
146.
Samad, F,
Yamamoto K,
and
Loskutoff DJ.
Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide.
J Clin Invest
97:
37-46,
1996
147.
Sappino, AP,
Huarle J,
Vassalli JD,
and
Belin D.
Sites of synthesis of urokinase and tissue-type plasminogen activators in the murine kidney.
J Clin Invest
87:
962-970,
1991[ISI][Medline].
148.
Sawdey, M,
Podor TJ,
and
Loskutoff DJ.
Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. Induction by transforming growth factor-beta, lipopolysaccharide, and tumor necrosis factor-alpha.
J Biol Chem
264:
10396-10401,
1989
149.
Sawdey, MS,
and
Loskutoff DJ.
Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo.
J Clin Invest
88:
1346-1353,
1991[ISI][Medline].
150.
Sawdey, MS,
and
Loskutoff DJ.
Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta.
J Clin Invest
88:
1346-1353,
1991[ISI][Medline].
151.
Schneider, DJ,
and
Sobel BE.
Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: implications for vascular disease in hyperinsulinemic states.
Proc Natl Acad Sci USA
88:
9959-9963,
1991[Abstract].
152.
Scott, RW,
Bergman BL,
Bajpai A,
Hersh RT,
Rodriguez H,
Jones BN,
Barreda C,
Watts S,
and
Baker JB.
Protease nexin. Properties and a modified purification procedure.
J Biol Chem
260:
7029-7034,
1985
153.
Shihab, FS,
Andoh TF,
Tanner AM,
Noble NA,
Border WA,
Franceschini N,
and
Bennett WM.
Role of transforming growth factor-1 in experimental chronic cyclosporine nephropathy.
Kidney Int
49:
1141-1151,
1996[ISI][Medline].
154.
Shihab, FS,
Bennett WM,
Tanner AM,
and
Andoh TF.
Mechanism of fibrosis in experimental tacrolimus nephrotoxicity.
Transplantation
64:
1829-1837,
1997[ISI][Medline].
155.
Shihab, FS,
Yamamoto T,
Nast CC,
Cohen AH,
Noble NA,
Gold LI,
and
Border WA.
Transforming growth factor-beta and matrix protein expression in acute and chronic rejection of human renal allografts.
J Am Soc Nephrol
6:
286-294,
1995[Abstract].
156.
Sitko, A,
Hervio L,
and
Loskutoff D.
Plasminogen activator inhibitors.
In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice, edited by Colman R.. Philadelphia, PA: Lippincott Williams & Wilkins, 2001, p. 355-364.
157.
Sitrin, RG,
Pan PM,
Blackwood RA,
Huang J,
and
Petty HR.
Cutting edge: evidence for a signaling partnership between urokinase receptors (CD87) and L-selectin (CD62L) in human polymorphonuclear neutrophils.
J Immunol
166:
4822-4825,
2001
158.
Sperti, G,
van Leeuwen R,
Maseri A,
and
Kluft C.
Platelet-derived growth factor increases plasminogen activator inhibitor-1 activity and mRNA in rat cultured vascular smooth muscle.
Ann NY Acad Sci
667:
178-180,
1992[ISI][Medline].
159.
Sprouse, JT,
Wong CS,
Chandler WL,
Williams GD,
Watkins SL,
and
Tarr PI.
Thrombogenic alleles, Escherichia coli O157:H7 infections, and hemolytic uremic syndrome.
Blood Coagul Fibrinolysis
12:
283-288,
2001[ISI][Medline].
160.
Stefansson, S,
and
Lawrence DA.
The serpin PAI1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin.
Nature
383:
441-443,
1996[ISI][Medline].
161.
Sugatani, J,
Igarashi T,
Munakata M,
Komiyama Y,
Takahashi H,
Komiyama N,
Maeda T,
Takeda T,
and
Miwa M.
Activation of coagulation in C57BL/6 mice given verotoxin 2 (VT2) and the effect of co-administration of LPS with VT2.
Thromb Res
100:
61-72,
2000[ISI][Medline].
162.
Tamaki, K,
Okuda S,
Nakayama M,
Yanagida T,
and
Fujishima M.
Transforming growth factor-beta 1 in hypertensive renal injury in Dahl salt-sensitive rats.
J Am Soc Nephrol
7:
2578-2589,
1996[Abstract].
163.
Tang, WH,
Friess H,
di Mola FF,
Schilling M,
Maurer C,
Graber HU,
Dervenis C,
Zimmermann A,
and
Buchler MW.
Activation of the serine proteinase system in chronic kidney rejection.
Transplantation
65:
1628-1634,
1998[ISI][Medline].
164.
Tang, WW,
Feng L,
Xia Y,
and
Wilson CB.
Extracellular matrix accumulation in immune-mediated tubulointerstitial injury.
Kidney Int
45:
1077-1084,
1994[ISI][Medline].
165.
Taylor, CM,
Williams JM,
Lote CJ,
Howie AJ,
Thewles A,
Wood JA,
Milford DV,
Raafat F,
Chant I,
and
Rose PE.
A laboratory model of toxin-induced hemolytic uremic syndrome.
Kidney Int
55:
1367-1374,
1999[ISI][Medline].
166.
Tomooka, S,
Border WA,
Marshall BC,
and
Noble NA.
Glomerular matrix accumulation is linked to inhibition of the plasmin protease system.
Kidney Int
42:
1462-1469,
1992[ISI][Medline].
167.
Troyer, DA,
Chandrasekar B,
Thinnes T,
Stone A,
Loskutoff DJ,
and
Fernandes G.
Effects of energy intake on type 1 plasminogen activator inhibitor levels in glomeruli of lupus-prone B/W mice.
Am J Pathol
146:
111-120,
1995[Abstract].
168.
Vassalli, JD,
Baccino D,
and
Belin D.
A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase.
J Cell Biol
100:
86-92,
1985[Abstract].
169.
Vaughan, DE,
Lazos SA,
and
Tong K.
Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis.
J Clin Invest
95:
995-1001,
1995[ISI][Medline].
170.
Wagner, SN,
Atkinson MJ,
Wagner C,
Hofler H,
Schmitt M,
and
Wilhelm O.
Sites of urokinase-type plasminogen activator expression and distribution of its receptor in the normal human kidney.
Histochem Cell Biol
105:
53-60,
1996[ISI][Medline].
171.
Wang, AY,
Poon P,
Lai FM,
Yu L,
Choi PC,
Lui SF,
and
Li PK.
Plasminogen activator inhibitor-1 gene polymorphism 4G/4G genotype and lupus nephritis in Chinese patients.
Kidney Int
59:
1520-1528,
2001[ISI][Medline].
172.
Wang, Y,
Pratt JR,
Hartley B,
Evans B,
Zhang L,
and
Sacks SH.
Expression of tissue type plasminogen activator and type 1 plasminogen activator inhibitor, and persistent fibrin deposition in chronic renal allograft failure.
Kidney Int
52:
371-377,
1997[ISI][Medline].
173.
Wang, Y,
Thompson EM,
Whawell SA,
and
Fleming KA.
Expression and localization of plasminogen activator inhibitor 1 mRNA in transplant kidneys.
J Pathol
169:
445-450,
1993[ISI][Medline].
174.
Wei, Y,
Waltz DA,
Rao N,
Drummond RJ,
Rosenberg S,
and
Chapman HA.
Identification of the urokinase receptor as an adhesion receptor for vitronectin.
J Biol Chem
269:
32380-32388,
1994
175.
Whitelock, JM,
Murdoch AD,
Iozzo RV,
and
Underwood PA.
The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases.
J Biol Chem
271:
10079-10086,
1996
176.
Wojta, J,
Kaun C,
Breuss JM,
Koshelnick Y,
Beckmann R,
Hattey E,
Mildner M,
Weninger W,
Nakamura T,
Tschachler E,
and
Binder BR.
Hepatocyte growth factor increases expression of vascular endothelial growth factor and plasminogen activator inhibitor-1 in human keratinocytes and the vascular endothelial growth factor receptor flk-1 in human endothelial cells.
Lab Invest
79:
427-438,
1999[ISI][Medline].
177.
Wolf, G,
Mueller E,
Stahl RAK,
and
Ziyadeh FN.
Angiotensin II induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-.
J Clin Invest
92:
1366-1372,
1993[ISI][Medline].
178.
Wolf, G,
and
Ziyadeh FN.
The role of angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanisms.
Am J Kidney Dis
29:
153-163,
1997[ISI][Medline].
179.
Xu, Y,
Hagege J,
Mougenot B,
Sraer JD,
Rønne E,
and
Rondeau E.
Different expression of the plasminogen activation system in renal thrombotic microangiopathy and the normal human kidney.
Kidney Int
50:
2011-2019,
1996[ISI][Medline].
180.
Xu, Y,
Zacharias U,
Peraldi MN,
He CJ,
Lu C,
Sraer JD,
Brass LF,
and
Rondeau E.
Constitutive expression and modulation of the functional thrombin receptor in the human kidney.
Am J Pathol
146:
101-110,
1995[Abstract].
181.
Yamada, N,
Arinami T,
Yamakawa-Kobayashi K,
Watanabe H,
Sohda S,
Hamada H,
Kubo T,
and
Hamaguchi H.
The 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene is associated with severe preeclampsia.
J Hum Genet
45:
138-141,
2000[ISI][Medline].
182.
Yamamoto, K,
and
Loskutoff DJ.
The kidneys of mice with autoimmune disease acquire a hypofibrinolytic/procoagulant state that correlates with the development of glomerulonephritis and tissue microthrombosis.
Am J Pathol
151:
725-734,
1997[Abstract].
183.
Yamamoto, T,
Nakamura T,
Noble NA,
Ruoslahti E,
and
Border WA.
Expression of transforming growth factor is elevated in human and experimental diabetic nephropathy.
Proc Natl Acad Sci USA
90:
1814-1818,
1993[Abstract].
184.
Yamamoto, T,
Noble NA,
Cohen AH,
Nast CC,
Hishida A,
Gold LI,
and
Border WA.
Expression of transforming growth factor- isoforms in human glomerular diseases.
Kidney Int
49:
461-469,
1996[ISI][Medline].
185.
Yeh, LC,
Mikhailov V,
and
Lee JC.
Regulation of expression of plasminogen activator inhibitor-1 in cultured rat osteoblastic cells by osteogenic protein-1 (BMP-7).
J Cell Biochem
81:
46-54,
2001[Medline].
186.
Zhang, G,
Kim H,
Cai X,
Lopez-Guisa J,
and
Eddy A.
Urokinase receptor deficiency modulates cellular and angiogenic responses in obstructive uropathy (Abstract).
J Am Soc Nephrol
12:
723,
2001.
187.
Zhang, G,
Kim H,
Cai X,
Lopez-Guisa J,
and
Eddy A.
Urokinase receptor deficiency promotes fibrosis in response to unilateral ureteral obstruction (Abstract).
J Am Soc Nephrol
12:
722,
2001.
188.
Zhao, W,
O'Malley Y,
and
Robbins ME.
Irradiation of rat mesangial cells alters the expression of gene products associated with the development of renal fibrosis.
Radiat Res
152:
160-169,
1999[ISI][Medline].
189.
Zhao, W,
Spitz DR,
Oberley LW,
and
Robbins ME.
Redox modulation of the pro-fibrogenic mediator plasminogen activator inhibitor-1 following ionizing radiation.
Cancer Res
61:
5537-5543,
2001
190.
Zidovetzki, R,
Wang JL,
Kim JA,
Chen P,
Fisher M,
and
Hofman FM.
Endothelin-1 enhances plasminogen activator inhibitor-1 production by human brain endothelial cells via protein kinase C-dependent pathway.
Arterioscler Thromb Vasc Biol
19:
1768-1775,
1999
191.
Ziyadeh, FN,
Hoffman BB,
Han DC,
Iglesias-De La Cruz MC,
Hong SW,
Isono M,
Chen S,
McGowan TA,
and
Sharma K.
Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice.
Proc Natl Acad Sci USA
97:
8015-8020,
2000